RICHARD DYER: Open Payments
NPI 1720676489 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$231 in 11 payments from 9 companies in 2025. Trend: 2023 $82 · 2024 $351 · 2025 $231
Food & beverage: $231
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 3 | $59 |
| Gilead Sciences, Inc. | 1 | $30 |
| Daiichi Sankyo Inc. | 1 | $29 |
| SANOFI PASTEUR INC. | 1 | $26 |
| Biogen, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $18 |
| MEDICOMP INC | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| AstraZeneca Pharmaceuticals LP | 1 | $14 |
Products named: QULIPTA, INJECTAFER, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, SPINRAZA, MOUNJARO, TELEPATCH CARDIAC MONITOR, REXULTI, UBRELVY.
Industry payments across PA — which companies pay providers there.
